$バーパックス・ファーマシューティカルズ(VRPX.US)$Reuters· 1 min ago Virpax Pharmaceuticals Inc - Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief
$バーパックス・ファーマシューティカルズ(VRPX.US)$ NEWS Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™ Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine....
$バーパックス・ファーマシューティカルズ(VRPX.US)$Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
$バーパックス・ファーマシューティカルズ(VRPX.US)$Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
バーパックス・ファーマシューティカルズに関するコメント
Update
Virpax Pharmaceuticals Inc - Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief
NEWS
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine....
Update
News
The vote was YES!
Pump and dump
10Q compliance Pop?
Up 54% AH
no news
Hello there
low float watch
まだコメントはありません